Outputs (202)

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups (2019)
Journal Article
Rueda, O. M., Sammut, S.-J., Seoane, J. A., Chin, S.-F., Caswell-Jin, J. L., Callari, M., Batra, R., Pereira, B., Bruna, A., Ali, H. R., Provenzano, E., Liu, B., Parisien, M., Gillett, C., McKinney, S., Green, A. R., Murphy, L., Purushotham, A., Ellis, I. O., Pharoah, P. D., …Curtis, C. (2019). Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature, 567(7748), 399–404. https://doi.org/10.1038/s41586-019-1007-8

The rates and routes of lethal systemic spread in breast cancer are poorly understood owing to a lack of molecularly characterized patient cohorts with long-term, detailed follow-up data. Long-term follow-up is especially important for those with oes... Read More about Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma (2019)
Journal Article
Kader, T., Hill, P., Zethoven, M., Goode, D. L., Elder, K., Thio, N., Doyle, M., Semple, T., Sufyan, W., Byrne, D. J., Pang, J.-M. B., Murugasu, A., Miligy, I. M., Green, A. R., Rakha, E. A., Fox, S. B., Mann, G. B., Campbell, I. G., & Gorringe, K. L. (2019). Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. Journal of Pathology, 248(3), 326-338. https://doi.org/10.1002/path.5262

The current model for breast cancer progression proposes independent “low‐grade (LG) like” and “high‐grade (HG) like” pathways but lacks a known precursor to HG cancer. We applied low coverage whole genome sequencing to atypical ductal hyperplasia (A... Read More about Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma.

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment (2019)
Journal Article
Abdel-Fatah, T. M., Broom, R. J., Lu, J., Moseley, P. M., Huang, B., Li, L., Liu, S., Chen, L., Ma, R. Z., Cao, W., Wang, X., Li, Y., Perry, J. K., Aleskandarany, M., Nolan, C. C., Rakha, E. A., Lobie, P. E., Chan, S. Y., Ellis, I. O., Hwang, L.-A., …Liu, D.-X. (2019). SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. British Journal of Cancer, 120(7), 728–745. https://doi.org/10.1038/s41416-019-0405-x

BACKGROUND: SHON nuclear expression (SHON-Nuc+) was previously reported to predict clinical outcomes to tamoxifen therapy in ERα+ breast cancer (BC). Herein we determined if SHON expression detected by specific monoclonal antibodies could provide a m... Read More about SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.

Clinicopathological significance of ataxia-telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3 related (ATR) kinase in MYC overexpressed breast cancers (2019)
Journal Article
Savva, C., De Souza, K., Ali, R., Rakha, E. A., Green, A. R., & Madhusudan, S. (2019). Clinicopathological significance of ataxia-telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3 related (ATR) kinase in MYC overexpressed breast cancers. Breast Cancer Research and Treatment, 175(1), 105–115. https://doi.org/10.1007/s10549-018-05113-8

Purpose: MYC transcription factor has critical roles in cell growth, proliferation, metabolism, differentiation, transformation and angiogenesis. MYC overexpression is seen in about 15% of breast cancers and linked to aggressive phenotypes. MYC overe... Read More about Clinicopathological significance of ataxia-telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3 related (ATR) kinase in MYC overexpressed breast cancers.

Liver kinase B1—a potential therapeutic target in hormone-sensitive breast cancer in older women (2019)
Journal Article
Syed, B. M., Green, A. R., Morgan, D. A., Ellis, I. O., & Cheung, K.-L. (2019). Liver kinase B1—a potential therapeutic target in hormone-sensitive breast cancer in older women. Cancers, 11(2), 1-17. https://doi.org/10.3390/cancers11020149

Background: The role of liver kinase B1 (LKB1), a serine/threonine kinase, has been described in the development of PeutzJagher’s syndrome, where a proportion (~45%) of patients have developed breast cancer in their lifetime. Cell line studies have l... Read More about Liver kinase B1—a potential therapeutic target in hormone-sensitive breast cancer in older women.

The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer (2019)
Journal Article
El-Ansari, R., El Ansari, R., Craze, M. L., Alfarsi, L., Soria, D., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2019). The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer. Breast Cancer Research and Treatment, 175(1), 27-38. https://doi.org/10.1007/s10549-018-05111-w

Purpose: Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity, and patient outcome. Glutamine availability for growth and progression of BC is important in several BC sub... Read More about The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.

Expression of Lamin A/C in early-stage breast cancer and its prognostic value (2019)
Journal Article
Alhudiri, I., Nolan, C., Ellis, I., Elzagheid, A., Rakha, E., Green, A., & Chapman, C. (2019). Expression of Lamin A/C in early-stage breast cancer and its prognostic value. Breast Cancer Research and Treatment, 174(3), 661–668. https://doi.org/10.1007/s10549-018-05092-w

Purpose: Lamins A/C, a major component of the nuclear lamina, plays key roles in maintaining nuclear integrity, regulation of gene expression, cell proliferation and apoptosis. Reduced lamin A/C expression in cancer has been reported to be a sign of... Read More about Expression of Lamin A/C in early-stage breast cancer and its prognostic value.

Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer (2018)
Journal Article
Joseph, C., Arshad, M., Kurozomi, S., Althobiti, M., Miligy, I. M., Al-Izzi, S., Toss, M. S., Goh, F. Q., Johnston, S. J., Martin, S. G., Ellis, I. O., Mongan, N. P., Green, A. R., & Rakha, E. A. (2019). Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. Breast Cancer Research and Treatment, 174(2), 387-399. https://doi.org/10.1007/s10549-018-05085-9

Purpose
CD133/ prominin 1 is a cancer stem cell marker associated with cancer progression and patient outcome in a variety of solid tumours, but its role in invasive breast cancer (BC) remains obscure. The current study aims to assess the prognostic... Read More about Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.

Connexin 43 is an independent predictor of patient outcome in breast cancer patients (2018)
Journal Article
Chasampalioti, M., Green, A. R., Ellis, I. O., Rakha, E. A., Jackson, A. M., Spendlove, I., & Ramage, J. M. (2019). Connexin 43 is an independent predictor of patient outcome in breast cancer patients. Breast Cancer Research and Treatment, 174(1), 93-102. https://doi.org/10.1007/s10549-018-5063-9

Purpose

Gap junctions are specialized membrane structures that form channels between adjacent cells allowing cell communication. Gap junctions and specifically Connexin 43 (Cx43) are down-regulated in cancer; however, there are contrasting reports... Read More about Connexin 43 is an independent predictor of patient outcome in breast cancer patients.

Glutamate dehydrogenase (GLUD1) expression in breast cancer (2018)
Journal Article
Craze, M. L., El-Ansari, R., Aleskandarany, M. A., Cheng, K. W., Al-Farsi, L., Masisi, B., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2019). Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Research and Treatment, 174(1), 79–91. https://doi.org/10.1007/s10549-018-5060-z

Dysregulated cellular metabolism is regarded as one of the hallmarks of cancer with some tumours utilising the glutamine metabolism pathway for their sustained proliferation and survival. Glutamate dehydrogenase (GLUD1) is a key enzyme in glutaminoly... Read More about Glutamate dehydrogenase (GLUD1) expression in breast cancer.